Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project].
Jaén A, Casabona J, Esteve A, Miró JM, Tural C, Ferrer E, Riera M, Segura F, Force L, Sued O, Vilaró J, Masabeu A, García I, Dorca E, Altès J, Navarro G, Podzamczer D, Villalonga C, Clotet B, Gatell JM; Grupo de Estudio PISCIS. Jaén A, et al. Med Clin (Barc). 2005 Apr 16;124(14):525-31. doi: 10.1157/13073938. Med Clin (Barc). 2005. PMID: 15847748 Spanish.
Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain).
Jaén A, Esteve A, Miró JM, Tural C, Montoliu A, Ferrer E, Riera M, Segura F, Force L, Sued O, Vilaró J, Garcia I, Masabeu A, Altès J, Coltet B, Podzamczer D, Murillas J, Navarro G, Gatell JM, Casabona J; PISCIS Study Group. Jaén A, et al. J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):212-20. doi: 10.1097/qai.0b013e31815ee282. J Acquir Immune Defic Syndr. 2008. PMID: 18297762
Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.
HIV-CAUSAL Collaboration; Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA. HIV-CAUSAL Collaboration, et al. Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6. Clin Infect Dis. 2015. PMID: 25567330 Free PMC article.
Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review.
Palacio-Vieira J, Reyes-Urueña JM, Imaz A, Bruguera A, Force L, Llaveria AO, Llibre JM, Vilaró I, Borràs FH, Falcó V, Riera M, Domingo P, de Lazzari E, Miró JM, Casabona J; PICIS study group. Palacio-Vieira J, et al. BMC Public Health. 2021 Aug 28;21(1):1596. doi: 10.1186/s12889-021-11613-y. BMC Public Health. 2021. PMID: 34454444 Free PMC article. Review.
Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012).
Monge S, Díez M, Alvarez M, Guillot V, Iribarren JA, Palacios R, Delgado R, Jaén A, Blanco JR, Domingo P, Portilla J, Pérez Elías MJ, Garcia F; Cohorte de la Red de Investigación en Sida (CoRIS). Monge S, et al. Among authors: jaen a. Clin Microbiol Infect. 2015 Jan;21(1):105.e1-5. doi: 10.1016/j.cmi.2014.08.007. Epub 2014 Oct 29. Clin Microbiol Infect. 2015. PMID: 25636937 Free article.
Drug use and antiretroviral therapy (ART) interactions: a qualitative study to explore the knowledge, beliefs, adherence, and quality of life of people living with HIV taking ART and illicit drugs.
Fuster-RuizdeApodaca MJ, Castro-Granell V, Laguía A, Jaén Á, Cenoz S, Galindo MJ. Fuster-RuizdeApodaca MJ, et al. Among authors: jaen a. AIDS Res Ther. 2020 May 24;17(1):24. doi: 10.1186/s12981-020-00279-y. AIDS Res Ther. 2020. PMID: 32448214 Free PMC article.
110 results